Grootendorst PV - Search Results

1

Does it matter whom and how you ask? inter- and intra-rater agreement in the Ontario Health Survey.

Grootendorst PV, Feeny DH, Furlong W. Grootendorst PV, et al. J Clin Epidemiol. 1997 Feb;50(2):127-35. doi: 10.1016/s0895-4356(96)00314-9. J Clin Epidemiol. 1997. PMID: 9120505

2

Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study.

Choi SK, Boyle E, Burchell AN, Gardner S, Collins E, Grootendorst P, Rourke SB; OHTN Cohort Study Group. Choi SK, et al. PLoS One. 2015 Nov 13;10(11):e0142706. doi: 10.1371/journal.pone.0142706. eCollection 2015. PLoS One. 2015. PMID: 26566285 Free PMC article.

3

A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee.

Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW. Grootendorst P, et al. J Rheumatol. 2007 Mar;34(3):534-42. J Rheumatol. 2007. PMID: 17343301

4

A comparison of alternative models of prescription drug utilization.

Grootendorst PV. Grootendorst PV. Health Econ. 1995 May-Jun;4(3):183-98. doi: 10.1002/hec.4730040304. Health Econ. 1995. PMID: 7550769

5

On becoming 65 in Ontario. Effects of drug plan eligibility on use of prescription medicines.

Grootendorst PV, O'Brien BJ, Anderson GM. Grootendorst PV, et al. Med Care. 1997 Apr;35(4):386-98. doi: 10.1097/00005650-199704000-00008. Med Care. 1997. PMID: 9107206

6

Censoring in statistical models of health status: what happens when one can do better than '1'.

Grootendorst P. Grootendorst P. Qual Life Res. 2000;9(8):911-4. doi: 10.1023/a:1008938429316. Qual Life Res. 2000. PMID: 11284210 No abstract available.

7

Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey.

Grootendorst P, Feeny D, Furlong W. Grootendorst P, et al. Med Care. 2000 Mar;38(3):290-9. doi: 10.1097/00005650-200003000-00006. Med Care. 2000. PMID: 10718354

8

Health care policy evaluation using longitudinal insurance claims data: an application of the panel Tobit estimator.

Grootendorst PV. Grootendorst PV. Health Econ. 1997 Jul-Aug;6(4):365-82. doi: 10.1002/(sici)1099-1050(199707)6:4<365::aid-hec279>3.0.co;2-e. Health Econ. 1997. PMID: 9285230

9

Cost analysis of dialysis treatments for end-stage renal disease (ESRD).

Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Goeree R, et al. Clin Invest Med. 1995 Dec;18(6):455-64. Clin Invest Med. 1995. PMID: 8714789

10

Estimating the clinical cost of drug development for orphan versus non-orphan drugs.

Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Jayasundara K, et al. Orphanet J Rare Dis. 2019 Jan 10;14(1):12. doi: 10.1186/s13023-018-0990-4. Orphanet J Rare Dis. 2019. PMID: 30630499 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results